Proteasome Inhibitor Attenuates Skeletal Muscle Reperfusion Injury by Blocking the Pathway of Nuclear Factor-κB Activation

Abstract

Bortezomib effectively blocks nuclear factor-kappaB activation in attenuating muscle reperfusion injury through inhibiting nuclear factor-kappaB inhibitory protein degradation. Therefore, inhibition of proteasome activity may provide a novel therapeutic strategy for the treatment of skeletal muscle reperfusion injury.